Literature DB >> 2195547

A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.

L Pearson1, J Garcia, F Wu, N Modesti, J Nelson, R Gaynor.   

Abstract

Regulation of human immunodeficiency virus (HIV) gene expression is dependent on specific regulatory regions in the long terminal repeat. These regions include the enhancer, SP1, "TATA," and trans-activating (TAR) regions. In addition, viral regulatory proteins such as tat and rev are important in regulating HIV gene expression. The mechanism of tat activation remains the subject of investigation, but effects at both transcriptional and posttranscriptional levels seem likely. Previous mutagenesis of the tat protein revealed that the amino terminus, the cysteine-rich domain, and the basic domain were all required for complete tat activation. Mutants of other viral trans-acting regulatory proteins, including E1A, tax, and VM65, have been identified that were capable of antagonizing the activity of their corresponding wild-type proteins. We wished to determine whether mutants of the tat protein could be identified that exhibited a similar phenotype. One mutant (delta tat) that truncated the basic domain of tat resulted in a transdominant phenotype inhibiting tat-induced gene expression of the HIV long terminal repeat but not other viral promoters. This mutant exhibited its maximal phenotype in cotransfection experiments when present in an 8- to 30-fold molar excess over the wild-type tat gene. Trans-activation of the HIV long terminal repeat by delta tat was very defective at the DNA concentrations used in these experiments. RNase protection analysis indicated that this mutant decreased tat-induced steady-state mRNA levels of the HIV long terminal repeat. Second-site mutations of the delta tat gene in either the amino terminus or cysteine region eliminated the transdominant phenotype. In contrast to tat, which was localized predominantly to the nucleolus, delta tat was present in both the nucleus and cytoplasm, suggesting that it may inhibit tat function by preventing nucleolar localization. Transdominant mutants of tat may have a role in potentially inhibiting HIV gene expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195547      PMCID: PMC54265          DOI: 10.1073/pnas.87.13.5079

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region.

Authors:  R Gaynor; E Soultanakis; M Kuwabara; J Garcia; D S Sigman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.

Authors:  A D Frankel; S Biancalana; D Hudson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein.

Authors:  J Hauber; M H Malim; B R Cullen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.

Authors:  M J Selby; E S Bain; P A Luciw; B M Peterlin
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

5.  Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function.

Authors:  M H Malim; S Böhnlein; J Hauber; B R Cullen
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

6.  Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.

Authors:  M Green; M Ishino; P M Loewenstein
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

7.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

Authors:  D Trono; M B Feinberg; D Baltimore
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

8.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

10.  HIV-1 TAT "activates" presynthesized RNA in the nucleus.

Authors:  M Braddock; A Chambers; W Wilson; M P Esnouf; S E Adams; A J Kingsman; S M Kingsman
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

View more
  45 in total

1.  Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.

Authors:  B Elangovan; T Subramanian; G Chinnadurai
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.

Authors:  S Emiliani; C Van Lint; W Fischle; P Paras; M Ott; J Brady; E Verdin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 3.  Functional roles of HIV-1 Tat protein in the nucleus.

Authors:  Yana R Musinova; Eugene V Sheval; Carla Dib; Diego Germini; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2015-10-27       Impact factor: 9.261

4.  Mutations in the activation region of herpes simplex virus regulatory protein ICP27 can be trans dominant.

Authors:  I L Smith; R E Sekulovich; M A Hardwicke; R M Sandri-Goldin
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  trans-dominant mutants of E1A provide genetic evidence that the zinc finger of the trans-activating domain binds a transcription factor.

Authors:  L C Webster; R P Ricciardi
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

6.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Differential Effects of Strategies to Improve the Transduction Efficiency of Lentiviral Vector that Conveys an Anti-HIV Protein, Nullbasic, in Human T Cells.

Authors:  Lina Rustanti; Hongping Jin; Dongsheng Li; Mary Lor; Haran Sivakumaran; David Harrich
Journal:  Virol Sin       Date:  2018-03-14       Impact factor: 4.327

8.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Targeting tat inhibitors in the assembly of human immunodeficiency virus type 1 transcription complexes.

Authors:  Iván D'Orso; Jocelyn R Grunwell; Robert L Nakamura; Chandreyee Das; Alan D Frankel
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.